Hugh MacKinnon, Chair of the Ontario Brain Institute’s Board of Directors, is delighted to announce that after an extensive international search, Dr. Tom Mikkelsen will join OBI as President & Scientific Director.

Following a distinguished career in the U.S. as one of the top neuro-oncologists with the Henry Ford Medical Group, Dr. Mikkelsen will be returning to his native Canada to drive the Ontario Brain Institute forward as its new leader. Dr. Mikkelsen received his MD from the University of Calgary and completed clinical training in neurology at the Montreal Neurological Institute.

Following this, he did postdoctoral training in tumour and molecular biology at the Ludwig Institute for Cancer Research in Montreal and then in La Jolla, California. Since 1992, he has led the brain tumour program at Henry Ford Hospital and was responsible for building the clinical trials program and laboratory of tumour biology. Together with other scientists, he helped assemble the Hermelin Brain Tumor Center, a leader in the understanding of the genetics of brain tumours and in the development of treatments for brain tumours. As Co-Director, he participated in the organization’s development on many levels spanning from face-to-face clinical care, to clinical trials, and translational and bench research.

In his new role, Dr. Mikkelsen will spearhead OBI’s management team to maximize the impact of neuroscience and the position of Ontario as a world leader in brain research, commercialization and care.

To learn more about OBI, join us at: www.braininstitute.ca.